デフォルト表紙
市場調査レポート
商品コード
1470700

全身性強皮症治療市場:地域別(北米、欧州、アジア太平洋、ラテンアメリカ、中東アフリカ):世界の産業分析、規模、シェア、成長、動向、予測、2024-2031年

Systemic Scleroderma Treatment Market by Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

出版日: | 発行: Persistence Market Research | ページ情報: 英文 380 Pages | 納期: 2~5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.89円
全身性強皮症治療市場:地域別(北米、欧州、アジア太平洋、ラテンアメリカ、中東アフリカ):世界の産業分析、規模、シェア、成長、動向、予測、2024-2031年
出版日: 2024年04月23日
発行: Persistence Market Research
ページ情報: 英文 380 Pages
納期: 2~5営業日
  • 全表示
  • 概要
  • 目次
概要

この調査レポートは世界の全身性強皮症治療市場を詳細に分析しています。この包括的なレポートは、主要な市場力学、成長促進要因、課題、新興動向に関する貴重な洞察を提供します。ヘルスケア産業における全身性強皮症治療セグメントの詳細な概要を提供し、2024年から2031年までの市場成長軌道を予測する独占データと統計を提示しています。

主な洞察

  • 全身性強皮症治療市場規模(2024年):12億米ドル
  • 予測市場価値(2031年):41億5,000万米ドル
  • 世界市場成長率(CAGR 2024年~2031年):8.0%

全身性強皮症治療市場- レポート範囲:

全身性強皮症治療市場は、全身性強皮症としても知られる全身性硬化症の症状や合併症の管理を目的とした、医薬品、生物学的製剤、支持療法介入を幅広く網羅しています。この自己免疫疾患は複数の臓器や組織に影響を及ぼし、線維化、血管機能障害、免疫異常などを引き起こします。市場開拓の利害関係者には、ヘルスケアプロバイダー、製薬会社、学術研究機関、患者支援団体などが含まれ、全身性強皮症患者のための効果的な治療選択肢を開発し提供するために協力しています。市場成長の原動力は、有病率の増加、治療法の進歩、個別化医療と患者中心のケアの重視の高まりです。

市場促進要因:

世界の全身性強皮症治療市場は、いくつかの主要な市場促進要因の恩恵を受けています。全身性強皮症に対する意識の高まりと診断技術の向上は、疾患の早期発見と診断に貢献し、タイムリーな介入と治療開始を可能にします。さらに、免疫学、分子生物学、標的治療の進歩は、線維化、炎症、自己免疫に関与する特定の経路に対処する、全身性強皮症管理のための新規薬理学的薬剤および生物学的製剤の開発につながりました。さらに、共同研究、臨床試験、患者登録は、全身性強皮症のバイオマーカー、予測因子、治療標的の発見と検証を促進し、技術革新と市場拡大を促進しています。

市場抑制要因:

大きな成長が見込まれるもの、全身性強皮症治療市場は、疾患の不均一性、治療のばらつき、患者の転帰に関する課題に直面しています。全身性強皮症は、限局性皮膚強皮症からびまん性皮膚強皮症までの臨床表現型のスペクトルを包含し、それぞれが明確な病態生理学的メカニズムと治療反応を有します。この異質性が疾患管理と治療方針の決定を複雑にし、治療成績と患者の反応性にばらつきをもたらしています。さらに、疾患の病因と進行に関する理解が乏しく、臨床試験デザインとエンドポイントの選択にもギャップがあるため、新規の全身性強皮症治療薬の開発と承認が妨げられています。これらの課題に対処するためには、治療効果を最適化し、全身性強皮症患者のケアを個別化するために、集学的協力、患者層別化戦略、適応試験デザインが必要です。

市場機会:

全身性強皮症治療市場は、技術革新、連携、患者中心のケアモデルによって大きな成長機会がもたらされます。精密医療、バイオマーカー探索、デジタルヘルス技術などの新たな動向は、全身性硬化症患者の個別化診断、治療、モニタリングに新たな道を提供します。新規治療標的、疾患修飾薬、および併用療法の同定は、異なる全身性強皮症のサブタイプや病期に対して、より効果的で的を絞った治療レジメンの開発を可能にします。さらに、患者参加、アドボカシー、および教育イニシアチブは、全身性強皮症患者が積極的に治療に参加し、治療アドヒアランスを高め、健康転帰を改善する力を与えます。戦略的パートナーシップ、研究コンソーシアム、および規制上の優遇措置は、科学的発見を臨床的に意義のある治療法に転換することを促進し、全身性強皮症管理の革新と市場成長を促進します。

本レポートで扱う主な質問

  • 全身性強皮症治療市場の世界の成長を促進する要因は何か?
  • 免疫学、分子生物学、標的治療における進歩は、全身性強皮症の治療状況をどのように変えているか?
  • 全身性強皮症セグメントにおいて、ヘルスケアプロバイダーや製薬会社が直面する主な課題と機会は何か?
  • 全身性強皮症管理における患者の転帰を改善する可能性が最も高い治療法と治療標的は何か?
  • アンメットニーズに対応し、全身性強皮症治療市場におけるイノベーションを推進するために、主要企業はどのような戦略を採用しているのか?

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲/ 分類
  • 市場の定義/ 範囲/ 制限
  • 含まれるものと含まれないも

第3章 主要な市場動向

  • 市場に影響を与える主な動向
  • イノベーション/開発動向

第4章 重要成功要因

  • 新薬の承認
  • メーカーが従う主要戦略
  • 薬物の採用/使用分析
  • 規制シナリオ
  • 疾病疫学
  • パイプライン評価

第5章 市場背景

  • マクロ経済要因
  • 予測要因- 関連性と影響
  • 市場力学

第6章 COVID19危機分析

  • COVID19の現在の統計と今後の影響の可能性
  • 現在のGDP予測と予想される影響
  • 回復シナリオ-短期、中期、長期の影響
  • COVID19とその影響分析、2023年の市場シナリオ

第7章 全身性強皮症治療の世界市場の需要分析(金額および規模)

  • 過去の市場金額(金額)分析、2019-2023年
  • 現在および将来の市場金額(金額)予測、2024~2031年
    • 前年比成長動向分析
    • 絶対的な$機会分析

第8章 全身性強皮症治療の世界市場分析と予測、対象臓器別

  • イントロダクション/主な調査結果
  • 過去の市場分析(金額)、2019~2023年
  • 現在および将来の市場予測(金額)、2024~2031年
    • 皮膚線維症
    • 筋骨格
    • 指の潰瘍
    • 肺動脈高血圧
    • 胃腸
    • 肺線維症
    • 強皮症腎クリーゼ
  • ターゲット臓器別市場魅力度分析

第9章 全身性強皮症治療の世界市場分析と予測、治療タイプ別

  • イントロダクション/主な調査結果
  • 過去の市場分析(金額)、2019~2023年
  • 現在および将来の市場予測(金額)、2024~2031年
    • 薬物セラピー
      • コルチコステロイド
      • 免疫抑制剤
      • 非ステロイド性抗炎症薬
      • カルシウムチャネル遮断薬
      • プロトンポンプ阻害剤
      • TNF阻害剤
      • エンドセリン受容体拮抗薬
      • ホスホジエステラーゼ5阻害剤
      • アンジオテンシン変換酵素
      • 造血幹細胞移植(HSCT)
  • ターゲット臓器別市場魅力度分析

第10章 全身性強皮症治療の世界市場分析と予測、投与経路別

  • イントロダクション/主な調査結果
  • 過去の市場分析(金額)、2019~2023年
  • 現在および将来の市場予測(金額)、2024~2031年
    • 注射
    • 経口
    • 外用
  • 投与経路別の市場魅力度分析

第11章 全身性強皮症治療の世界市場分析と予測、流通チャネル別

  • イントロダクション/主な調査結果
  • 過去の市場分析(金額)、2019~2023年
  • 現在および将来の市場予測(金額)、2024~2031年
    • 病院薬局
    • 専門クリニック
    • 小売薬局
    • オンライン薬局
  • 流通チャネル別市場魅力度分析

第12章 全身性強皮症治療の世界市場分析と予測、地域別

  • イントロダクション
  • 過去の市場規模(金額)分析、2019-2023年
  • 現在の市場規模(金額)分析と予測、2024~2031年
    • 北米
    • ラテンアメリカ
    • 欧州
    • 東アジア
    • 南アジア
    • オセアニア
    • 中東およびアフリカ(MEA)
  • 地域別市場魅力度分析

第13章 北米全身性強皮症治療市場分析と予測

第14章 ラテンアメリカの全身性強皮症治療市場分析と予測

第15章 欧州全身性強皮症治療市場分析と予測

第16章 南アジアの全身性強皮症治療市場分析と予測

第17章 東アジア全身性強皮症治療市場分析と予測

第18章 オセアニア全身性強皮症治療市場分析と予測

第19章 中東およびアフリカ(MEA)全身性強皮症治療市場分析と予測

第20章 市場構造分析

  • 企業階層別市場分析
  • 主要企業の市場シェア分析
  • 市場プレゼンス分析

第21章 競合分析

  • 競合ダッシュボード
  • 競合ベンチマーク
  • 競合の詳細
    • Pfizer Inc.
    • Novartis AG
    • GlaxoSmithKline plc.
    • Sanofi SA
    • Lupin Ltd
    • Cipla Ltd
    • Teva Pharmaceuticals
    • Johnson &Johnson Services Inc.
    • Bayer Healthcare LLC
    • F. Hoffmann-La Roche Ltd
    • Amgen Inc
    • Zydus Lifesciences Ltd
    • Casper Pharma
    • Boehringer Ingelheim Pharmaceuticals, Inc
    • Organon LLC
    • Accord Healthcare Inc

第22章 使用される前提条件と頭字語

第23章 調査手法

目次
Product Code: PMRREP33054

Persistence Market Research, a renowned market research firm, has conducted an exhaustive analysis of the global Systemic Scleroderma Treatment Market. This comprehensive report provides valuable insights into key market dynamics, growth drivers, challenges, and emerging trends. It offers a detailed overview of the systemic scleroderma treatment segment within the healthcare industry, presenting exclusive data and statistics projecting the market's growth trajectory from 2024 to 2031.

Key Insights:

  • Systemic Scleroderma Treatment Market Size (2024): US$ 1.20 Bn
  • Projected Market Value (2031): US$ 4.15 Bn
  • Global Market Growth Rate (CAGR 2024 to 2031): 8.0%

Systemic Scleroderma Treatment Market - Report Scope:

The Systemic Scleroderma Treatment Market encompasses a wide range of pharmaceuticals, biologics, and supportive care interventions aimed at managing the symptoms and complications of systemic sclerosis, also known as systemic scleroderma. This autoimmune disease affects multiple organs and tissues, leading to fibrosis, vascular dysfunction, and immune dysregulation. Market stakeholders include healthcare providers, pharmaceutical companies, academic research institutions, and patient advocacy groups, collaborating to develop and deliver effective treatment options for systemic scleroderma patients. Market growth is driven by increasing disease prevalence, advancements in treatment modalities, and growing emphasis on personalized medicine and patient-centered care.

Market Growth Drivers:

The global Systemic Scleroderma Treatment Market benefits from several key growth drivers. Rising awareness about systemic sclerosis and improved diagnostic techniques contribute to the early detection and diagnosis of the disease, enabling timely intervention and treatment initiation. Moreover, advancements in immunology, molecular biology, and targeted therapies have led to the development of novel pharmacological agents and biologics for systemic scleroderma management, addressing specific pathways involved in fibrosis, inflammation, and autoimmunity. Additionally, collaborative research efforts, clinical trials, and patient registries facilitate the discovery and validation of biomarkers, predictive factors, and therapeutic targets for systemic scleroderma, driving innovation and market expansion.

Market Restraints:

Despite its significant growth prospects, the Systemic Scleroderma Treatment Market faces challenges related to disease heterogeneity, treatment variability, and patient outcomes. Systemic sclerosis encompasses a spectrum of clinical phenotypes, ranging from limited cutaneous scleroderma to diffuse cutaneous scleroderma, each with distinct pathophysiological mechanisms and treatment responses. This heterogeneity complicates disease management and therapeutic decision-making, leading to variability in treatment outcomes and patient responses. Moreover, limited understanding of disease etiology and progression, as well as gaps in clinical trial design and endpoint selection, hinder the development and regulatory approval of novel systemic scleroderma therapies. Addressing these challenges requires multidisciplinary collaboration, patient stratification strategies, and adaptive trial designs to optimize treatment efficacy and personalize care for systemic sclerosis patients.

Market Opportunities:

The Systemic Scleroderma Treatment Market presents significant growth opportunities driven by innovation, collaboration, and patient-centric care models. Emerging trends such as precision medicine, biomarker discovery, and digital health technologies offer new avenues for personalized diagnosis, treatment, and monitoring of systemic sclerosis patients. The identification of novel therapeutic targets, disease-modifying agents, and combination therapies enables the development of more effective and targeted treatment regimens for different systemic scleroderma subtypes and disease stages. Furthermore, patient engagement, advocacy, and education initiatives empower systemic sclerosis patients to actively participate in their care, enhance treatment adherence, and improve health outcomes. Strategic partnerships, research consortia, and regulatory incentives facilitate the translation of scientific discoveries into clinically meaningful therapies, driving innovation and market growth in systemic scleroderma management.

Key Questions Answered in the Report:

  • What factors are driving the growth of the Systemic Scleroderma Treatment Market globally?
  • How are advancements in immunology, molecular biology, and targeted therapies reshaping the treatment landscape of systemic sclerosis?
  • What are the key challenges and opportunities facing healthcare providers and pharmaceutical companies in the systemic scleroderma segment?
  • Which treatment modalities and therapeutic targets offer the highest potential for improving patient outcomes in systemic scleroderma management?
  • What strategies are leading companies employing to address unmet needs and drive innovation in the systemic scleroderma treatment market?

Competitive Intelligence and Business Strategy:

Leading players in the global Systemic Scleroderma Treatment Market, including pharmaceutical companies, biotechnology firms, and academic research centers, focus on innovation, collaboration, and patient-centricity to drive market growth and improve clinical outcomes. These companies invest in research and development to discover and develop novel therapies targeting key pathways implicated in systemic sclerosis pathogenesis, such as fibrosis, autoimmunity, and vascular dysfunction. Moreover, strategic partnerships with patient advocacy groups, academic consortia, and regulatory agencies enable companies to leverage patient insights, scientific expertise, and regulatory support for drug development and commercialization. Furthermore, emphasis on real-world evidence generation, patient-reported outcomes, and health economic analyses enhances value proposition and market access for systemic scleroderma therapies.

Key Companies Profiled:

  • Pfizer Inc.
  • Novartis AG
  • GlaxoSmithKline plc.
  • Sanofi SA
  • Lupin Ltd
  • Cipla Ltd
  • Teva Pharmaceuticals
  • Johnson & Johnson Services Inc.
  • Bayer Healthcare LLC
  • F. Hoffmann-La Roche Ltd
  • Amgen Inc
  • Zydus Lifesciences Ltd
  • Casper Pharma
  • Boehringer Ingelheim Pharmaceuticals, Inc
  • Organon LLC
  • Accord Healthcare Inc

Systemic Scleroderma Treatment Market Research Segmentation:

Systemic Scleroderma Treatment Market by Target Organ:

  • Skin Fibrosis
  • Musculoskeletal
  • Digital Ulcers
  • Pulmonary Arterial Hypertension
  • Gastrointestinal
  • Pulmonary Fibrosis
  • Scleroderma Renal Crisis

Systemic Scleroderma Treatment Market by Treatment Type:

  • Drug Therapy
  • Corticosteroids
  • Immunosuppressants
  • Nonsteroidal Anti-Inflammatory Drugs
  • Calcium Channel Blockers
  • Proton Pump Inhibitors
  • TNF Inhibitors
  • Endothelin Receptor Antagonists
  • Phosphodiesterase Type 5 Inhibitors
  • Angiotensin-Converting Enzyme
  • Hematopoietic Stem Cell Transplantation (HSCT)

Systemic Scleroderma Treatment Market by Route of Administration:

  • Injectable Systemic Scleroderma Drugs
  • Oral Systemic Scleroderma Drugs
  • Topical Systemic Scleroderma Drugs

Systemic Scleroderma Treatment Market by Distribution Channel:

  • Hospital Pharmacies
  • Speciality Clinics
  • Retail Pharmacies
  • Online Pharmacies

Systemic Scleroderma Treatment Market by Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • The Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions & Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Innovation / Development Trends

4. Key Success Factors

  • 4.1. New Drug Approvals
  • 4.2. Key Strategies Followed By Manufacturers
  • 4.3. Drug Adoption / Usage Analysis
  • 4.4. Regulatory Scenario
  • 4.5. Disease Epidemiology
  • 4.6. Pipeline Assessment

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Outlook
    • 5.1.3. Per Capita Healthcare Expenditure Outlook
    • 5.1.4. Global Pharmaceutical Market Outlook
    • 5.1.5. Rare Disease Market Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Top Companies Historical Growth
    • 5.2.2. Product Adoption Rate and Demand
    • 5.2.3. New Product Launches
    • 5.2.4. Increase in rate of skin diseases
    • 5.2.5. Increase in air pollution
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID19 Crisis Analysis

  • 6.1. Current COVID19 Statistics and Probable Future Impact
  • 6.2. Current GDP Projection and Probable Impact
  • 6.3. Recovery Scenario - Short term, Midterm and Long Term Impact
  • 6.4. COVID19 and Impact Analysis, 2023 Market Scenario

7. Global Systemic Scleroderma Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2031

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2031
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Systemic Scleroderma Treatment Market Analysis 2019-2023 and Forecast 2024-2031, by Target Organ

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis, By Target Organ, 2019-2023
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Target Organ, 2024-2031
    • 8.3.1. Skin Fibrosis
    • 8.3.2. Musculoskeletal
    • 8.3.3. Digital Ulcers
    • 8.3.4. Pulmonary Arterial Hypertension
    • 8.3.5. Gastrointestinal
    • 8.3.6. Pulmonary Fibrosis
    • 8.3.7. Scleroderma Renal Crisis
  • 8.4. Market Attractiveness Analysis, By Target Organ

9. Global Systemic Scleroderma Treatment Market Analysis 2019-2023 and Forecast 2024-2031, by Therapy Type

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis, By Therapy Type, 2019-2023
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Therapy Type, 2024-2031
    • 9.3.1. Drug Therapy
      • 9.3.1.1. Corticosteroids
      • 9.3.1.2. Immunosuppressants
      • 9.3.1.3. Nonsteroidal Anti-Inflammatory Drugs
      • 9.3.1.4. Calcium Channel Blockers
      • 9.3.1.5. Proton Pump Inhibitors
      • 9.3.1.6. TNF Inhibitors
      • 9.3.1.7. Endothelin Receptor Antagonists
      • 9.3.1.8. Phosphodiesterase Type 5 Inhibitors
      • 9.3.1.9. Angiotensin-Converting Enzyme
      • 9.3.1.10. Hematopoietic Stem Cell Transplantation (HSCT)
  • 9.4. Market Attractiveness Analysis, By Target Organ

10. Global Systemic Scleroderma Treatment Market Analysis 2019-2023 and Forecast 2024-2031, by Route of Administration

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Mn) Analysis, By Route of Administration, 2019-2023
  • 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2024-2031
    • 10.3.1. Injectable
    • 10.3.2. Oral
    • 10.3.3. Topical
  • 10.4. Market Attractiveness Analysis, By Route of Administration

11. Global Systemic Scleroderma Treatment Market Analysis 2019-2023 and Forecast 2024-2031, by Distribution Channel

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2019-2023
  • 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2024-2031
    • 11.3.1. Hospital Pharmacies
    • 11.3.2. Specialty Clinics
    • 11.3.3. Retail Pharmacies
    • 11.3.4. Online Pharmacies
  • 11.4. Market Attractiveness Analysis, By Distribution Channel

12. Global Systemic Scleroderma Treatment Market Analysis 2019-2023 and Forecast 2024-2031, by Region

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2023
  • 12.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2031
    • 12.3.1. North America
    • 12.3.2. Latin America
    • 12.3.3. Europe
    • 12.3.4. East Asia
    • 12.3.5. South Asia
    • 12.3.6. Oceania
    • 12.3.7. Middle East and Africa (MEA)
  • 12.4. Market Attractiveness Analysis, By Region

13. North America Systemic Scleroderma Treatment Market Analysis 2019-2023 and Forecast 2024-2031

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) Trend Analysis, By Market Taxonomy, 2019-2023
  • 13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
    • 13.3.1. By Country
      • 13.3.1.1. U.S.
      • 13.3.1.2. Canada
    • 13.3.2. By Target Organ
    • 13.3.3. By Therapy Type
    • 13.3.4. By Route of Administration
    • 13.3.5. By Distribution Channel
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Target Organ
    • 13.4.3. By Therapy Type
    • 13.4.4. By Route of Administration
    • 13.4.5. By Distribution Channel
  • 13.5. Market Trends
  • 13.6. Key Market Participants - Intensity Mapping
  • 13.7. Drivers and Restraints - Impact Analysis
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. U.S. Systemic Scleroderma Treatment Market
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Target Organ
        • 13.8.1.2.2. By Therapy Type
        • 13.8.1.2.3. By Route of Administration
        • 13.8.1.2.4. By Distribution Channel
    • 13.8.2. Canada Systemic Scleroderma Treatment Market
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.2.2.1. By Target Organ
        • 13.8.2.2.2. By Therapy Type
        • 13.8.2.2.3. By Route of Administration
        • 13.8.2.2.4. By Distribution Channel

14. Latin America Systemic Scleroderma Treatment Market Analysis 2019-2023 and Forecast 2024-2031

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) Trend Analysis, By Market Taxonomy, 2019-2023
  • 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
    • 14.3.1. By Country
      • 14.3.1.1. Brazil
      • 14.3.1.2. Mexico
      • 14.3.1.3. Rest of Latin America
    • 14.3.2. By Target Organ
    • 14.3.3. By Therapy Type
    • 14.3.4. By Route of Administration
    • 14.3.5. By Distribution Channel
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Target Organ
    • 14.4.3. By Therapy Type
    • 14.4.4. By Route of Administration
    • 14.4.5. By Distribution Channel
  • 14.5. Market Trends
  • 14.6. Key Market Participants - Intensity Mapping
  • 14.7. Drivers and Restraints - Impact Analysis
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. Brazil Systemic Scleroderma Treatment Market
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Target Organ
        • 14.8.1.2.2. By Therapy Type
        • 14.8.1.2.3. By Route of Administration
        • 14.8.1.2.4. By Distribution Channel
    • 14.8.2. Argentina Systemic Scleroderma Treatment Market
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Target Organ
        • 14.8.2.2.2. By Therapy Type
        • 14.8.2.2.3. By Route of Administration
        • 14.8.2.2.4. By Distribution Channel
    • 14.8.3. Mexico Systemic Scleroderma Treatment Market
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.3.2.1. By Target Organ
        • 14.8.3.2.2. By Therapy Type
        • 14.8.3.2.3. By Route of Administration
        • 14.8.3.2.4. By Distribution Channel

15. Europe Systemic Scleroderma Treatment Market Analysis 2019-2023 and Forecast 2024-2031

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) Trend Analysis, By Market Taxonomy, 2019-2023
  • 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
    • 15.3.1. By Country
      • 15.3.1.1. Germany
      • 15.3.1.2. Italy
      • 15.3.1.3. France
      • 15.3.1.4. U.K.
      • 15.3.1.5. Spain
      • 15.3.1.6. BENELUX
      • 15.3.1.7. Russia
      • 15.3.1.8. Rest of Europe
    • 15.3.2. By Target Organ
    • 15.3.3. By Therapy Type
    • 15.3.4. By Route of Administration
    • 15.3.5. By Distribution Channel
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Target Organ
    • 15.4.3. By Therapy Type
    • 15.4.4. By Route of Administration
    • 15.4.5. By Distribution Channel
  • 15.5. Market Trends
  • 15.6. Key Market Participants - Intensity Mapping
  • 15.7. Drivers and Restraints - Impact Analysis
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. Germany Systemic Scleroderma Treatment Market
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Target Organ
        • 15.8.1.2.2. By Therapy Type
        • 15.8.1.2.3. By Route of Administration
        • 15.8.1.2.4. By Distribution Channel
    • 15.8.2. France Systemic Scleroderma Treatment Market
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Target Organ
        • 15.8.2.2.2. By Therapy Type
        • 15.8.2.2.3. By Route of Administration
        • 15.8.2.2.4. By Distribution Channel
    • 15.8.3. Italy Systemic Scleroderma Treatment Market
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Target Organ
        • 15.8.3.2.2. By Therapy Type
        • 15.8.3.2.3. By Route of Administration
        • 15.8.3.2.4. By Distribution Channel
    • 15.8.4. Spain Systemic Scleroderma Treatment Market
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.4.2.1. By Target Organ
        • 15.8.4.2.2. By Therapy Type
        • 15.8.4.2.3. By Route of Administration
        • 15.8.4.2.4. By Distribution Channel
    • 15.8.5. U.K. Systemic Scleroderma Treatment Market
      • 15.8.5.1. Introduction
      • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.5.2.1. By Target Organ
        • 15.8.5.2.2. By Therapy Type
        • 15.8.5.2.3. By Route of Administration
        • 15.8.5.2.4. By Distribution Channel
    • 15.8.6. Benelux Union Systemic Scleroderma Treatment Market
      • 15.8.6.1. Introduction
      • 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.6.2.1. By Target Organ
        • 15.8.6.2.2. By Therapy Type
        • 15.8.6.2.3. By Route of Administration
        • 15.8.6.2.4. By Distribution Channel
    • 15.8.7. Russia Systemic Scleroderma Treatment Market
      • 15.8.7.1. Introduction
      • 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.7.2.1. By Target Organ
        • 15.8.7.2.2. By Therapy Type
        • 15.8.7.2.3. By Route of Administration
        • 15.8.7.2.4. By Distribution Channel

16. South Asia Systemic Scleroderma Treatment Market Analysis 2019-2023 and Forecast 2024-2031

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) Trend Analysis, By Market Taxonomy, 2019-2023
  • 16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
    • 16.3.1. By Country
      • 16.3.1.1. India
      • 16.3.1.2. Thailand
      • 16.3.1.3. Indonesia
      • 16.3.1.4. Malaysia
      • 16.3.1.5. Rest of South Asia
    • 16.3.2. By Target Organ
    • 16.3.3. By Therapy Type
    • 16.3.4. By Route of Administration
    • 16.3.5. By Distribution Channel
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Target Organ
    • 16.4.3. By Therapy Type
    • 16.4.4. By Route of Administration
    • 16.4.5. By Distribution Channel
  • 16.5. Market Trends
  • 16.6. Key Market Participants - Intensity Mapping
  • 16.7. Drivers and Restraints - Impact Analysis
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. India Systemic Scleroderma Treatment Market
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Target Organ
        • 16.8.1.2.2. By Therapy Type
        • 16.8.1.2.3. By Route of Administration
        • 16.8.1.2.4. By Distribution Channel
    • 16.8.2. Indonesia Systemic Scleroderma Treatment Market
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Target Organ
        • 16.8.2.2.2. By Therapy Type
        • 16.8.2.2.3. By Route of Administration
        • 16.8.2.2.4. By Distribution Channel
    • 16.8.3. Malaysia Systemic Scleroderma Treatment Market
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.3.2.1. By Target Organ
        • 16.8.3.2.2. By Therapy Type
        • 16.8.3.2.3. By Route of Administration
        • 16.8.3.2.4. By Distribution Channel
    • 16.8.4. Thailand Systemic Scleroderma Treatment Market
      • 16.8.4.1. Introduction
      • 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.4.2.1. By Target Organ
        • 16.8.4.2.2. By Therapy Type
        • 16.8.4.2.3. By Route of Administration
        • 16.8.4.2.4. By Distribution Channel

17. East Asia Systemic Scleroderma Treatment Market Analysis 2019-2023 and Forecast 2024-2031

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) Trend Analysis, By Market Taxonomy, 2019-2023
  • 17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
    • 17.3.1. By Country
      • 17.3.1.1. China
      • 17.3.1.2. Japan
      • 17.3.1.3. South Korea
    • 17.3.2. By Target Organ
    • 17.3.3. By Therapy Type
    • 17.3.4. By Route of Administration
    • 17.3.5. By Distribution Channel
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Target Organ
    • 17.4.3. By Therapy Type
    • 17.4.4. By Route of Administration
    • 17.4.5. By Distribution Channel
  • 17.5. Market Trends
  • 17.6. Key Market Participants - Intensity Mapping
  • 17.7. Drivers and Restraints - Impact Analysis
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. China Systemic Scleroderma Treatment Market
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Target Organ
        • 17.8.1.2.2. By Therapy Type
        • 17.8.1.2.3. By Route of Administration
        • 17.8.1.2.4. By Distribution Channel
    • 17.8.2. Japan Systemic Scleroderma Treatment Market
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Target Organ
        • 17.8.2.2.2. By Therapy Type
        • 17.8.2.2.3. By Route of Administration
        • 17.8.2.2.4. By Distribution Channel
    • 17.8.3. South Korea Systemic Scleroderma Treatment Market
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.3.2.1. By Target Organ
        • 17.8.3.2.2. By Therapy Type
        • 17.8.3.2.3. By Route of Administration
        • 17.8.3.2.4. By Distribution Channel

18. Oceania Systemic Scleroderma Treatment Market Analysis 2019-2023 and Forecast 2024-2031

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Mn) Trend Analysis, By Market Taxonomy, 2019-2023
  • 18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
    • 18.3.1. By Country
      • 18.3.1.1. Australia
      • 18.3.1.2. New Zealand
    • 18.3.2. By Target Organ
    • 18.3.3. By Therapy Type
    • 18.3.4. By Route of Administration
    • 18.3.5. By Distribution Channel
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Target Organ
    • 18.4.3. By Therapy Type
    • 18.4.4. By Route of Administration
    • 18.4.5. By Distribution Channel
  • 18.5. Market Trends
  • 18.6. Key Market Participants - Intensity Mapping
  • 18.7. Drivers and Restraints - Impact Analysis
  • 18.8. Country Level Analysis & Forecast
    • 18.8.1. Australia Systemic Scleroderma Treatment Market
      • 18.8.1.1. Introduction
      • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.1.2.1. By Target Organ
        • 18.8.1.2.2. By Therapy Type
        • 18.8.1.2.3. By Route of Administration
        • 18.8.1.2.4. By Distribution Channel
    • 18.8.2. New Zealand Systemic Scleroderma Treatment Market
      • 18.8.2.1. Introduction
      • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.2.2.1. By Target Organ
        • 18.8.2.2.2. By Therapy Type
        • 18.8.2.2.3. By Route of Administration
        • 18.8.2.2.4. By Distribution Channel

19. Middle East and Africa (MEA) Systemic Scleroderma Treatment Market Analysis 2019-2023 and Forecast 2024-2031

  • 19.1. Introduction
  • 19.2. Historical Market Size (US$ Mn) Trend Analysis, By Market Taxonomy, 2019-2023
  • 19.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
    • 19.3.1. By Country
      • 19.3.1.1. GCC Countries
      • 19.3.1.2. Israel
      • 19.3.1.3. Turkey
      • 19.3.1.4. North Africa
      • 19.3.1.5. South Africa
      • 19.3.1.6. Rest of Middle East and Africa
    • 19.3.2. By Target Organ
    • 19.3.3. By Therapy Type
    • 19.3.4. By Route of Administration
    • 19.3.5. By Distribution Channel
  • 19.4. Market Attractiveness Analysis
    • 19.4.1. By Country
    • 19.4.2. By Target Organ
    • 19.4.3. By Therapy Type
    • 19.4.4. By Route of Administration
    • 19.4.5. By Distribution Channel
  • 19.5. Market Trends
  • 19.6. Key Market Participants - Intensity Mapping
  • 19.7. Drivers and Restraints - Impact Analysis
  • 19.8. Country Level Analysis & Forecast
    • 19.8.1. GCC Countries Systemic Scleroderma Treatment Market
      • 19.8.1.1. Introduction
      • 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.1.2.1. By Target Organ
        • 19.8.1.2.2. By Therapy Type
        • 19.8.1.2.3. By Route of Administration
        • 19.8.1.2.4. By Distribution Channel
    • 19.8.2. Turkey Systemic Scleroderma Treatment Market
      • 19.8.2.1. Introduction
      • 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.2.2.1. By Target Organ
        • 19.8.2.2.2. By Therapy Type
        • 19.8.2.2.3. By Route of Administration
        • 19.8.2.2.4. By Distribution Channel
    • 19.8.3. South Africa Systemic Scleroderma Treatment Market
      • 19.8.3.1. Introduction
      • 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.3.2.1. By Target Organ
        • 19.8.3.2.2. By Therapy Type
        • 19.8.3.2.3. By Route of Administration
        • 19.8.3.2.4. By Distribution Channel
    • 19.8.4. North Africa Systemic Scleroderma Treatment Market
      • 19.8.4.1. Introduction
      • 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.4.2.1. By Target Organ
        • 19.8.4.2.2. By Therapy Type
        • 19.8.4.2.3. By Route of Administration
        • 19.8.4.2.4. By Distribution Channel

20. Market Structure Analysis

  • 20.1. Market Analysis, By Tier of Companies
  • 20.2. Market Share Analysis of Top Players
  • 20.3. Market Presence Analysis

21. Competition Analysis

  • 21.1. Competition Dashboard
  • 21.2. Competition Benchmarking
  • 21.3. Competition Deep Dive
    • 21.3.1. Pfizer Inc.
      • 21.3.1.1. Overview
      • 21.3.1.2. Product Portfolio
      • 21.3.1.3. Key Financials
      • 21.3.1.4. SWOT Analysis
      • 21.3.1.5. Strategy Overview
      • 21.3.1.6. Key Developments
    • 21.3.2. Novartis AG
      • 21.3.2.1. Overview
      • 21.3.2.2. Product Portfolio
      • 21.3.2.3. Key Financials
      • 21.3.2.4. SWOT Analysis
      • 21.3.2.5. Strategy Overview
      • 21.3.2.6. Key Developments
    • 21.3.3. GlaxoSmithKline plc.
      • 21.3.3.1. Overview
      • 21.3.3.2. Product Portfolio
      • 21.3.3.3. Key Financials
      • 21.3.3.4. SWOT Analysis
      • 21.3.3.5. Strategy Overview
      • 21.3.3.6. Key Developments
    • 21.3.4. Sanofi SA
      • 21.3.4.1. Overview
      • 21.3.4.2. Product Portfolio
      • 21.3.4.3. Key Financials
      • 21.3.4.4. SWOT Analysis
      • 21.3.4.5. Strategy Overview
      • 21.3.4.6. Key Developments
    • 21.3.5. Lupin Ltd
      • 21.3.5.1. Overview
      • 21.3.5.2. Product Portfolio
      • 21.3.5.3. Key Financials
      • 21.3.5.4. SWOT Analysis
      • 21.3.5.5. Strategy Overview
      • 21.3.5.6. Key Developments
    • 21.3.6. Cipla Ltd
      • 21.3.6.1. Overview
      • 21.3.6.2. Product Portfolio
      • 21.3.6.3. Key Financials
      • 21.3.6.4. SWOT Analysis
      • 21.3.6.5. Strategy Overview
      • 21.3.6.6. Key Developments
    • 21.3.7. Teva Pharmaceuticals
      • 21.3.7.1. Overview
      • 21.3.7.2. Product Portfolio
      • 21.3.7.3. Key Financials
      • 21.3.7.4. SWOT Analysis
      • 21.3.7.5. Strategy Overview
      • 21.3.7.6. Key Developments
    • 21.3.8. Johnson & Johnson Services Inc.
      • 21.3.8.1. Overview
      • 21.3.8.2. Product Portfolio
      • 21.3.8.3. Key Financials
      • 21.3.8.4. SWOT Analysis
      • 21.3.8.5. Strategy Overview
      • 21.3.8.6. Key Developments
    • 21.3.9. Bayer Healthcare LLC
      • 21.3.9.1. Overview
      • 21.3.9.2. Product Portfolio
      • 21.3.9.3. Key Financials
      • 21.3.9.4. SWOT Analysis
      • 21.3.9.5. Strategy Overview
      • 21.3.9.6. Key Developments
    • 21.3.10. F. Hoffmann-La Roche Ltd
      • 21.3.10.1. Overview
      • 21.3.10.2. Product Portfolio
      • 21.3.10.3. Key Financials
      • 21.3.10.4. SWOT Analysis
      • 21.3.10.5. Strategy Overview
      • 21.3.10.6. Key Developments
    • 21.3.11. Amgen Inc
      • 21.3.11.1. Overview
      • 21.3.11.2. Product Portfolio
      • 21.3.11.3. Key Financials
      • 21.3.11.4. SWOT Analysis
      • 21.3.11.5. Strategy Overview
      • 21.3.11.6. Key Developments
    • 21.3.12. Zydus Lifesciences Ltd
      • 21.3.12.1. Overview
      • 21.3.12.2. Product Portfolio
      • 21.3.12.3. Key Financials
      • 21.3.12.4. SWOT Analysis
      • 21.3.12.5. Strategy Overview
      • 21.3.12.6. Key Developments
    • 21.3.13. Casper Pharma
      • 21.3.13.1. Overview
      • 21.3.13.2. Product Portfolio
      • 21.3.13.3. Key Financials
      • 21.3.13.4. SWOT Analysis
      • 21.3.13.5. Strategy Overview
      • 21.3.13.6. Key Developments
    • 21.3.14. Boehringer Ingelheim Pharmaceuticals, Inc
      • 21.3.14.1. Overview
      • 21.3.14.2. Product Portfolio
      • 21.3.14.3. Key Financials
      • 21.3.14.4. SWOT Analysis
      • 21.3.14.5. Strategy Overview
      • 21.3.14.6. Key Developments
    • 21.3.15. Organon LLC
      • 21.3.15.1. Overview
      • 21.3.15.2. Product Portfolio
      • 21.3.15.3. Key Financials
      • 21.3.15.4. SWOT Analysis
      • 21.3.15.5. Strategy Overview
      • 21.3.15.6. Key Developments
    • 21.3.16. Accord Healthcare Inc
      • 21.3.16.1. Overview
      • 21.3.16.2. Product Portfolio
      • 21.3.16.3. Key Financials
      • 21.3.16.4. SWOT Analysis
      • 21.3.16.5. Strategy Overview
      • 21.3.16.6. Key Developments

22. Assumptions and Acronyms Used

23. Research Methodology